Paper Details
- Home
- Paper Details
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Author: AmbrosioniJuan, BerrocalLeire, BlanchJordi, BlancoJose L, BorjabadBeatriz, ChiviteIvan, De La MoraLorena, De LazzariElisa, FoncillasAlberto, Gonzalez-CordonAna, InciarteAlexy, LagunoMontserrat, LlobetRoger, MallolasJosep, MartinezEsteban, Martinez-RebollarMaria, MiroJose M, RocabertAlba, RodriguezAna, SempereAbiu, SolbesEstela, TorresBerta
Original Abstract of the Article :
BACKGROUND: While both the burden of therapy and the individual drugs in bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine differ, it is unclear whether their real-life tolerability may be also different. METHODS: Single-centre, clinical cohort analysis of al...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1093/jac/dkad338
データ提供：米国国立医学図書館（NLM）
Comparing Bictegravir/Tenofovir Alafenamide/Emtricitabine and Dolutegravir/Lamivudine for HIV Maintenance Therapy
The fight against HIV is a continuous journey, like traversing a vast desert seeking a cure. This research compares the tolerability of two different antiretroviral regimens: bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) and dolutegravir/lamivudine. The study aimed to evaluate real-life tolerability and identify any differences between these regimens.
The researchers compared the discontinuation rates and adverse event profiles of these two regimens in a real-life setting. The results showed no significant difference in the risk of overall or toxicity-related discontinuations between the two regimens. This suggests that both regimens are well-tolerated in real-world settings.
Navigating HIV Treatment: Finding the Right Path
This study provides valuable information for doctors and patients navigating the complexities of HIV treatment. The findings suggest that both BIC/TAF/FTC and dolutegravir/lamivudine are well-tolerated options for long-term HIV maintenance therapy.
Personalized HIV Care: A Journey of Adaptability
This research underscores the importance of personalized HIV care. The study highlights the need to consider individual patient factors and preferences when choosing an antiretroviral regimen. It reminds us that the journey of HIV treatment is a constant process of adaptation, seeking the best path forward for each individual.
Dr. Camel's Conclusion
This study offers valuable insights into the real-world tolerability of two widely used antiretroviral regimens for HIV maintenance therapy. The findings suggest that both BIC/TAF/FTC and dolutegravir/lamivudine are well-tolerated options. This research underscores the importance of individualized care and careful consideration of patient factors when making treatment decisions. It reminds us that the journey of HIV treatment is a continuous process of adaptation and discovery, seeking the best path to a healthier future.
Date :
- Date Completed 2023-12-04
- Date Revised 2023-12-04
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.